The membrane-bound mucins: How large o-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies

Critical Reviews in Oncogenesis

Volumn 14, Issue 2-3, 2008, Pages 177-196

  Van Seuningen, Isabelle ^a   Jonckheere, Nicolas ^a  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

Author keywords

Cancer; Cell signaling; Chimioresistance; MUC1; MUC4; Mucin; Proliferation; Therapeutic target; Tumor progression

Indexed keywords

EPIDERMAL GROWTH FACTOR; GEMCITABINE; GLYCOPROTEIN; HYBRID PROTEIN; INTERLEUKIN 18; IODINE 131; MANNAN; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 4; PAM 4 ANTIBODY; PROLINE; SERINE; TAMOXIFEN; THREONINE; UNCLASSIFIED DRUG; MUC1 PROTEIN, HUMAN; MUC4 PROTEIN, HUMAN; MUC4 PROTEIN, RAT;

BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CELL FUNCTION; CELL MEMBRANE; CYTOPLASM; GENE STRUCTURE; HUMAN; HYDROPHOBICITY; LOW DRUG DOSE; LUNG METASTASIS; METASTASIS; MOLECULAR EVOLUTION; NONHUMAN; ORTHOLOGY; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RADIOIMMUNOTHERAPY; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; TUMOR GROWTH; ANIMAL; GENE THERAPY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PHYSIOLOGY;

ANIMALS; GENE THERAPY; GLYCOPROTEINS; HUMANS; IMMUNOTHERAPY; MUCIN-1; MUCIN-4; NEOPLASMS, GLANDULAR AND EPITHELIAL;

EID: 66349096961     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v14.i2-3.30     Document Type: Review

References (89)

1. Jonckheere N, Van Seuningen I. The ever growing family of membrane-bound mucins. In: Van Seuningen I, editor. The epithelial mucins: structure/function. Roles in cancer and inflammatory diseases. Kerala (India): Research Signpost; 2008. p. 17-38.
2. Swallow DM, Gendler S, Griffi ths B, Corney G, Taylor-Papadimitriou J, Bramwell ME. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature. 1987;328(6125):82-4.
3. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem. 1990;265(25):15294-9.
4. Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem. 1990;265(10):5573-8.
5. Lancaster CA, Peat N, Duhig T, Wilson D, Taylor-Papadimitriou J, Gendler SJ. Structureand expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem Biophys Res Commun. 1990;173(3):1019-29.
6. Fowler JC, Teixeira AS, Vinall LE, Swallow DM. Hypervariability of the membraneassociated mucin and cancer marker MUC1. Hum Genet. 2003;113(6):473-9.
7. Carvalho F, Seruca R, David L, Amorim A, Seixas M, Bennett E, Clausen H, Sobrinho- Simoes M. MUC1 gene polymorphism and gastric cancer-an epidemiological study. Glycoconj J. 1997;14(1):107-11.
8. Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organization and classification of the human mucin genes. Front Biosci. 2001;6:D1192-206.
9. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol. 1995;57:607-34.
10. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol. 2004;2:4.
11. Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH. The MUC1 SEA module is a self-cleaving domain. J Biol Chem. 2005;280(39):33374-86.
12. Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, Harris A. Identification of MUC1 proteolytic cleavage sites in vivo. Biochem Biophys Res Commun. 2001;283(3):715-20.
13. Pemberton LF, Rughetti A, Taylor-Papadimitriou J, Gendler SJ. The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. J Biol Chem. 1996;271(4):2332-40.
14. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta. 1999;1455(2-3):301-13.
15. Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A, Keydar I. Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem. 1990;189(3):463-73.
16. Zrihan-Licht S, Vos HL, Baruch A, Elroy-Stein O, Sagiv D, Keydar I, Hilkens J, Wreschner DH. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur J Biochem. 1994;224(2):787-95.
17. Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 1994;356(1):130-6.
18. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001;276(16):13057-64.
19. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6(3):339-53.
20. Li Y, Kufe D. The human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochem Biophys Res Commun. 2001;281(2):440-3.
21. Li Y, Chen W, Ren J, Yu WH, Li Q, Yoshida K, Kufe D. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol Ther. 2003;2(2):187-93.
22. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995;55(18):4000-3.
23. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and betacatenin. J Biol Chem. 2001;276(9):6061-4.
24. Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem. 2002;277(20):17616-22.
25. Ho JJ, Kim YS. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas. 1994;9(6):674-91.
26. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an antiadhesion molecule. Int J Cancer. 2000;88(4):507-18.
27. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J, Figdor CG. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol. 1993;151(2):767-76.
28. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129(1):255-65.
29. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinomaassociated antigen and beta-catenin in cell adhesion. J Biol Chem. 1997;272(19): 12492-4.
30. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Cell signaling through membrane mucins. Bioessays. 2003;25(1):66-71.
31. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of betacatenin.Cancer Res. 2005;65(22):10413-22.
32. Hattrup CL, Fernandez-Rodriguez J, Schroeder JA, Hansson GC, Gendler SJ. MUC1 can interact with adenomatous polyposis coli in breast cancer. Biochem Biophys Res Commun. 2004;316(2):364-9.
33. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti- apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fi broblasts. J Biol Chem. 2004;279(20):20607-12.
34. Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003;1(10):765-75.
35. Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, Kufe D. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007;282(27):19321-30.
36. Wei X, Xu H, Kufe D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 2007;67(4):1853-8.
37. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. MUC1 oncoprotein functions in activation of fi broblast growth factor receptor signaling. Mol Cancer Res. 2006;4(11):873-83.
38. Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor traffi cking. Oncogene. 2007;26(12):1693-701.
39. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, Gendler SJ, Hollingsworth MA. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res. 2007;67(11):5201-10.
40. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007;27(6):992-1004.
41. Rahn JJ, Shen Q, Mah BK, Hugh JC. MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J Biol Chem. 2004;279(28):29386- 90.
42. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004;5(2):163-75.
43. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003;278(37):35458-64.
44. Lee IJ, Han F, Baek J, Hisatsune A, Kim KC. Inhibition of MUC1 expression by indole- 3-carbinol. Int J Cancer. 2004;109(6):810-6.
45. Kalra AV, Campbell RB. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer. 2007;97(7):910-8.
46. Kalra AV, Campbell RB. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2009;45(1):164-73.
47. Spicer AP, Parry G, Patton S, Gendler SJ. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem. 1991;266(23):15099-109.
48. Lalani EN, Berdichevsky F, Boshell M, Shearer M, Wilson D, Stauss H, Gendler SJ, Taylor-Papadimitriou J. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J Biol Chem. 1991;266(23):15420-6.
49. Spicer AP, Duhig T, Chilton BS, Gendler SJ. Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mamm Genome. 1995;6(12):885-8.
50. Crepin M, Porchet N, Aubert JP, Degand P. Diversity of the peptide moiety of human airway mucins. Biorheology. 1990;27(3-4):471-84.
51. Porchet N, Nguyen VC, Dufosse J, Audie JP, Guyonnet-Duperat V, Gross MS, Denis C, Degand P, Bernheim A, Aubert JP. Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem Biophys Res Commun. 1991;175(2):414-22.
52. Gross MS, Guyonnet-Duperat V, Porchet N, Bernheim A, Aubert JP, Nguyen VC. Mucin 4 (MUC4) gene: regional assignment (3q29) and RFLP analysis. Ann Genet. 1992;35(1):21-6.
53. Escande F, Lemaitre L, Moniaux N, Batra SK, Aubert JP, Buisine MP. Genomic organization of MUC4 mucin gene. Towards the characterization of splice variants. Eur J Biochem. 2002;269(15):3637-44.
54. Moniaux N, Nollet S, Porchet N, Degand P, Laine A, Aubert JP. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochem J. 1999;338(Pt 2):325-33.
55. Nollet S, Moniaux N, Maury J, Petitprez D, Degand P, Laine A, Porchet N, Aubert JP. Human mucin gene MUC4: organization of its 5'-region and polymorphism of its central tandem repeat array. Biochem J. 1998;332(Pt 3):739-48.
56. Fowler J, Vinall L, Swallow D. Polymorphism of the human muc genes. Front Biosci. 2001;6:D1207-15.
57. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45-60.
58. Desseyn JL, Clavereau I, Laine A. Cloning, chromosomal localization and characterization of the murine mucin gene orthologous to human MUC4. Eur J Biochem. 2002;269(13):3150-9.
59. Carraway KL, Price-Schiavi SA, Komatsu M, Idris N, Perez A, Li P, Jepson S, Zhu X, Carvajal ME, Carraway CA. Multiple facets of sialomucin complex/MUC4, a membrane mucin and erbb2 ligand, in tumors and tissues (Y2K update). Front Biosci. 2000;5:D95-107.
60. Dekker J, Rossen JW, Buller HA, Einerhand AW. The MUC family: an obituary. Trends Biochem Sci. 2002;27(3):126-31.
61. Carraway CA, Carraway KL. Sequestration and segregation of receptor kinases in epithelial cells: implications for ErbB2 oncogenesis. Sci STKE. 2007;2007(381):re3.
62. Carraway KL III, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol. 2007;78:1-22.
63. Jepson S, Komatsu M, Haq B, Arango ME, Huang D, Carraway CA, Carraway KL. Muc4/ sialomucin complex, the intramembrane ErbB2 ligand, induces specifi c phosphorylationkinase or protein kinaseB/Akt pathways. Oncogene. 2002;21(49):7524-32. of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene.2002;21(49):7524-32.
64. Ciccarelli FD, Doerks T, Bork P. AMOP, a protein module alternatively spliced in cancer cells. Trends Biochem Sci. 2002;27(3):113-5.
65. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004;64(2): 622-30.
66. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin- resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65(2):473-82.
67. Van Seuningen I, Leteurtre E, Pigny P. Mucins in pancreas and hepato-biliary tract. Expression, regulation, biomarkers and therapy. In: Van Seuningen I, editor. The epithelial mucins: structure/function. Roles in cancer and infl ammatory diseases. Kerala (India): Research Signpost; 2008. p. 233-48.
68. Piessen G, Mariette C, Van Seuningen I. Mucin expression and regulation in oesophageal cancer: new molecular targets in cancer progression from Barrett's oesophagus to adenocarcinoma? In: Van Seuningen I, editor. The epithelial mucins: structure/ function. Roles in cancer and infl ammatory diseases. Kerala (India): Research Signpost; 2008. p. 169-82.
69. Wu K, Fregien N, Carraway KL. Molecular cloning and sequencing of the mucin subunit of a heterodimeric, bifunctional cell surface glycoprotein complex of ascites rat mammary adenocarcinoma cells. J Biol Chem. 1994;269(16):11950-5.
70. Lang T, Hansson GC, Samuelsson T. An inventory of mucin genes in the chicken genome shows that the mucin domain of Muc13 is encoded by multiple exons and that ovomucin is part of a locus of related gel-forming mucins. BMC Genomics. 2006;7:197.
71. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 1994;13(14):3302-11.
72. Ramsauer VP, Carraway CA, Salas PJ, Carraway KL. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem. 2003;278(32):30142-7.
73. Komatsu M, Carraway CA, Fregien NL, Carraway KL. Reversible disruption of cellmatrix and cell-cell interactions by overexpression of sialomucin complex. J Biol Chem. 1997;272(52):33245-54.
74. Jacob GS, Kirmaier C, Abbas SZ, Howard SC, Steininger CN, Welply JK, Scudder P. Binding of sialyl Lewis x to E-selectin as measured by fl uorescence polarization. Biochemistry. 1995;34(4):1210-7.
75. Komatsu M, Jepson S, Arango ME, Carothers Carraway CA, Carraway KL. Muc4/ sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene. 2001;20(4):461-70.
76. Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99(6):783-91.
77. Hu YP, Haq B, Carraway KL, Savaraj N, Lampidis TJ. Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol. 2003;65(9):1419-25.
78. Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines. 2008;7(7):951-62.
79. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines. 2008;7(7):963-75.
80. Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ. MUC1-specifi c cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin Cancer Res. 2001;7(3 Suppl):848s-55s.
81. Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. MUC1-specifi c CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J. 2001;18(11-12):931-42.
82. Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer. 2002;97(3):386-92.
83. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006;8(3):R27.
84. Baritaki S, Zafi ropoulos A, Georgopoulos E, Souris S, Krambovitis E. Generation of human anti-MUC3 IgG antibodies after in vitro immunization of naive peripheral blood B-lymphocytes. Cancer Immunol Immunother. 2001;50(2):109-14.
85. Snyder LA, Goletz TJ, Gunn GR, Shi FF, Harris MC, Cochlin K, McCauley C, McCarthy SG, Branigan PJ, Knight DM. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine. 2006;24(16):3340-52.
86. Shi FF, Gunn GR, Snyder LA, Goletz TJ. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases. Vaccine. 2007;25(17):3338-46.
87. Wei J, Gao W, Wu J, Meng K, Zhang J, Chen J, Miao Y. Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Cancer Biother Radiopharm. 2008;23(1):121-8.
88. Aberle S, Schug N, Mathlouthi R, Seitz G, Kupper JH, Schroder K, Blin N. Promoter selection for the cytosine deaminase suicide gene constructs in gastric cancer. Eur J Gastroenterol Hepatol. 2004;16(1):63-7.
89. Chen L, Liu Q, Qin R, Le H, Xia R, Li W, Kumar M. Amplifi cation and functional characterization of MUC1 promoter and gene-virotherapy via a targeting adenoviral vector expressing hSSTR2 gene in MUC1-positive Panc-1 pancreatic cancer cells in vitro. Int J Mol Med. 2005;15(4):617-26.